Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 7, 2000, Pages 929-935

  Andrade, R J ^a   Garcia Escano M D ^a   Valdivielso, P ^a   Alcantara R ^a   Sanchez Chaparro M A ^a   Gonzalez Santos P ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HEPATITIS C; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033938752     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00792.x     Document Type: Article

References (35)

1. 1 Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanism of action and clinical applications. J Am Med Assoc 1991; 266: 1375-83.
2. 2 Gutterman JU. Cytokine therapeutics: lessons from Interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-205.
3. 3 Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
4. 4 Lindsay KL. Therapy of hepatitis C. Overview. Hepatol 1997; 26 (Suppl. 1): 71S-77S.
5. 5 Shinohara E, Yamashita S, Kihara S, et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatol 1997; 25: 1502-6.
6. 6 Fernandez-Miranda C, Castellano G, Guijarro C, et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α. Am J Gastroenterol 1998; 93: 1901-4.
7. 7 Peñarrubia MJ, Steegmann JL, Lavilla E, et al. Hypertriglyceridemia may be severe in CML patients treated with interferon-α. Am J Hematol 1995; 49: 240-1.
8. 8 Sunderkötter C, Luger T, Kolde G. Severe hypertriglyceridaemia and interferon-α. Lancet 1993; 342: 1111-2.
9. 9 Graessle D, Bonacini M, Chen S. Alpha-interferon and reversible hypertriglyceridemia. Ann Intern Med 1993; 118: 316-7.
10. 10 Yamagishi S, Abe T, Sawada T. Human recombinant Interferon α-2a (rIFN α-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient. Am J Gastroenterol 1994; 89: 2280.
11. 11 Goodkin DE. Interferon β therapy for multiple sclerosis. Lancet 1998; 352: 1486-7.
12. 12 So K, Kioka K, Moriyoshi Y, et al. Changes in serum lipids in patients with chronic hepatitis C during Interferon beta therapy. Gastroenterology 1995; 108: A1174(Abstract).
13. 13 Kioka K, So K, Moriyoshi Y, et al. Comparison between the effects of Interferon α and Interferon β on lipid metabolism. Gastroenterology 1995; 108: A1098(Abstract).
14. 14 National Institutes of Health. Consensus Development Conference Panel statement: management of hepatitis C. Hepatol 1997; 26: 2S-10S.
15. 15 Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatol 1981; 1: 431-5.
16. 16 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum. J Clin Invest 1955; 374: 1345-53.
17. 17 Jackson R, Mc Lean L. Human postheparin plasma lipoprotein lipase and hepatic triglyceride lipase. Meth Enzymol 1991; 197: 339-45.
18. 18 Belfrage P, Vaughan M. Simple liquid-liquid partition system for isolation of labelled oleic acid from mixtures with glycerides. J Lipid Res 1969; 10: 341-4.
19. 19 Dixon RM, Bordes EC, Keim NL, et al. Decreases in serum high-density lipoprotein cholesterol and total cholesterol resulting from naturally produced recombinant DNA-derived leukocyte-interferons. Metabolism 1984; 33: 400-4.
20. 20 Massaro E, Borden E, Hawkins J, Wiebe D, Shrago E. Effects of recombinant interferon-α2 treatment upon lipid concentrations and lipoprotein composition. J Interferon Res 1986; 6: 655-65.
21. 21 Bengtsson-Olivecrona G, Olivecrona T. Assay of lipoprotein lipase and hepatic lipase. In: Converse CA, Skinner ER, eds. Lipoprotein Analysis. A Practical Approach Oxford: Oxford University Press, 1992: 169-85.
22. 22 Fesce E, Airoldi A, Mondazzi L, et al. Intramuscular beta Interferon for chronic hepatitis C. is it worth trying? Ital J Gastroenterol Hepatol 1998; 30: 185-8.
23. 23 Habertsetzer F, Marcellin P, Boyer N, et al. Recombinant Interferon beta for the treatment of chronic hepatitis C. Hepatol 1995; 22: 2.
24. 24 Rosenzweig B, Wiebe D, Borden E, Storer B, Shrago E. Plasma lipoportein changes in humans induced by β-interferon. Atherosclerosis 1987; 67: 261-7.
25. 25 Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41(Suppl.): 97-101.
26. 26 Ehnholm C, Aho K, Huttunen JK, et al. Effect of Interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982; 2: 68-73.
27. 27 Patton JS, Shepard HM, Wilking H, et al. Interferons and tumor necrosis factor have similar catabolic effects on 3T3-L1 cells. Proc Natl Acad Sci USA 1986; 83: 8313-7.
28. 28 Dinarello CA, Mier JW. Lymphokines. New Engl J Med 1987; 317: 940-5.
29. 29 Porat O. The effect of tumor necrosis factor alpha on the activity of lipoprotein lipase in adipose tissue. Lymphokine Res 1989; 8: 459-69.
30. 30 Patsch JR, Gotto AM Jr, Olivecrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoprotein in vitro. Proc Natl Acad Sci 1978; 75: 4519-23.
31. 31 Schectman G, Kaul S, Mueller RA, Borden EC, Kisseban AH. The effect of Interferon on the metabolism of LDLs. Arterioscler Thrombos 1992; 12: 1053-62.
32. 32 Cooper AD. Hepatic lipoprotein and cholesterol metabolism. In: Zakim D, Boyer TD, eds. Hepatology. A Textbook of Liver Disease, 2nd edn. Philadelphia: W.B. Saunders, 1990: 96-123.
33. 33 Bisgaier CL, Sieberker MU, Brown ML, et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceriderich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res 1991; 32: 21-33.
34. 34 Tall AR, Sammett D, Vita G, Deckelbaum RJ, Olivecrona T. Lipoprotein lipase enhances the cholesteryl ester transfer protein mediated transfer of cholesteryl esters from high density lipoproteins to very low density lipoproteins. J Biol Chem 1984; 259: 9587-94.
35. 35 Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinol 1989; 125: 267-4.